<DOC>
	<DOCNO>NCT01088516</DOCNO>
	<brief_summary>Therapeutic option prevent vertical transmission HIV remain limited . Combination antiretroviral therapy form HAART ( Highly Active Anti Retroviral Therapy ) generally recommend developed world , ability reduce maternal viral load , thus likelihood transmission , well prevention drug resistance mutation , might otherwise reduce future option therapy mother , infant , . Exclusive formula-feeding also recommend developed world ( clean water source &amp; adequate hygiene reliably available ) prevent HIV transmission breastmilk , however , yet feasible option many develop world setting due economic , infrastructure , social infant-health reason . The investigator propose use HAART regimen pregnancy breastfeed base upon recently release Aluvia tablet ( tablet form LOPINAVIR/RITONAVIR LOP ; establish capsule form know Kaletra ) improve maternal virological control thus mother-to-child-transmission ( MTCT ) . Hypothesis : Maternal use HAART contain Zidovudine , 3TC Aluvia ( Lopinavir/Ritonavir ) prevent antepartum , intrapartum transmission HIV , well allow exclusive subsequent complementary feeding carry minimum risk mother infant . - Study regimen : ZDV/3TC ( combivir ) + 2 Aluvia Tabs PO BID start 14-30 week gestational age ( GA ) continue labor long mother breastfeed - Peripartum single dose Nevirapine ( sdNVP ) ( Note : Mothers also receive ZDV part study regimen ) mother sdNVP + 5 day postpartum ZDV infant give per current Zambian practice - Exclusive breastfeeding ( EBF ) x 6 month complementary food add , aim gradual wean breastfeed infant age 12-13 month . In case inability wean 13 month , however , drug continue mother achieved complete wean . - Follow-up period : Mother &amp; child follow infant age 24 month , per schedule-of-visits ( approx every 3 month ) Major outcome measure : infant survival negative db ( dried blood spot ) PCR 3 month post wean .</brief_summary>
	<brief_title>Clinical Study Aluvia-based HAART Regimen Prevention Mother-to-child HIV Transmission Africa</brief_title>
	<detailed_description>Study complete . Results publish manuscript press June 2015 Ngoma MS , Misir A , Mutale W , Rampakakis E , Sampalis JS , Elong A , Chisele S , Mwale A , Mwansa JK , Mumba S , Chandwe M , Pilon R , Sandstrom P , Wu S , Yee K Silverman MS. Efficacy WHO recommendation continue breastfeed maternal cART prevention perinatal postnatal HIV transmission Zambia . Journal International AIDS Society ; 2015</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Minimum age 15 year Pregnancy ability initiate therapy 1430 week gestation HIV seropositivity Intention exclusively breastfeed 6 month Ability give inform consent Ability attend followup visit Previous HAART Preexisting known major illness likely influence pregnancy outcome place participant increase risk adverse event HAART therapy , include diabetes , severe renal , liver heart disease , active tuberculosis Severe anemia ( Hemoglobin &lt; 8 gm/dL ) Current continue therapy select medication either absolutely relatively contraindicated coadministration Aluvia</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Vertical Transmission</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Breastfeeding</keyword>
	<keyword>Prevention mother child transmission</keyword>
	<keyword>HAART</keyword>
	<keyword>Aluvia</keyword>
	<keyword>Lopinavir</keyword>
	<keyword>Africa</keyword>
	<keyword>Infectious Disease Transmission , Vertical</keyword>
</DOC>